25th Annual International AF SymposiumTM 2020 20

SYLLABUS Table of Contents CME Information / 2 Faculty / 4 Faculty Biographies / 11

25th Annual International AF Symposium 2020 January 23-25, 2020 CME Information Jointly provided by Postgraduate Institute for Medicine and Advanced Medical Education This activity is supported by an independent educational grant from Boston Scientific, Biosense Webster, Medtronic, and Abbott TARGET AUDIENCE This activity has been designed to meet the educational needs of cardiologists, internists, fellows, physician assistants, registered nurses, nurse practitioners, and other medical professionals involved in the care of patients with atrial fibrillation. EDUCATIONAL OBJECTIVES After completing this activity, the participant should be better able to: 1. Provide a current review of new information on the clinical science and pathophysiology of atrial fibrillation and atrial fibrillation-related 2. Provide a detailed presentation of the most recent developments in the diagnosis and treatment of atrial fibrillation 3. Discuss the prevention of AF-related stroke and other sequelae, with an emphasis on current and evolving pharmacological and nonpharmacological therapies and enabling new technologies in the field of cardiac electrophysiology 4. Exchange thoughts and techniques with the treatment team to improve the outcome of patient care and treatment 5. Provide appropriate care and counsel for patients and their families through the education of healthcare professionals JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Advanced Medical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

2 CME Information PHYSICIAN CONTINUING MEDICAL EDUCATION The Postgraduate Institute for Medicine designates this live activity for a maximum of 15.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. CONTINUING NURSING EDUCATION The maximum number of hours awarded for this Continuing Nursing Education activity is 15 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate. MOC STATEMENT Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 15.25 MOC in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. DISCLOSURE OF CONFLICTS OF INTEREST Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

3 Faculty Amin Al-Ahmad, MD States the following: Consulting Fees (e.g., advisory boards): Boston Scientific, Biosense Webster, Abbott, Cardiva Hugh Calkins, MD States the following: Consulting Fees (e.g., advisory boards): Biosense, Medtronic, Atricure, Boston Scientific, Abbott Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents (e.g., speakers’ bureaus):Medtronic, Biosense A. John Camm, MD States the following: Consulting Fees (e.g., advisory boards): Bayer, Daiichi Sankyo, Boston Scientific, Sanofi, Acesion, Correvio Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents (e.g., speakers’ bureaus): Bayer, Daiichi Sankyo, Boston Scientific, Sanofi, Acesion, Correvio Contracted Research: Bayer, Boehringer Ingelheim, Pfizer, aiichiD Sankyo, Abbott Stuart Connolly, MD States the following: Consulting Fees (e.g., advisory boards): Sanofi Aventis, Bayer, Portola, Boston Scientific, Javelin, Boehringer-Ingelheim, Bristol-Myers Squibb Contracted Research: Sanofi Aventis, Bayer, Boston Scientific, Boehringer-Ingelheim, Bristol-Myers Squibb Isabel Deisenhofer, MD States the following: Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents (e.g., speakers’ bureaus): Abbott, Biosense-Webster, Boston-Scientific (Speaker honoraria) Thomas Deneke, MD States the following: Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents (e.g., speakers’ bureaus): Speakers activity (Biotronik, Abbott), total amound 3.000 Luigi Di Biase, MD, PhD States the following: Consulting Fees (e.g., advisory boards): Biosense Webster, Stereotaxis, Abbott Speaker Honoraria, Travel Support: Biotronik, Medtronic, Boston Scientific, Bristol Meyers Squibb and PFizer. Jun Dong, MD States the following: Hereby states that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months Patrick Ellinor, MD, PhD States the following: Hereby states that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months Andrew Farb, MD States the following: Hereby states that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months

4 John Foran, MD States the following: Other: Proctoring Paul Friedman, MD States the following: Receipt of Intellectual Property Rights/Patent Holder : NeoChord, Preventice, Sorin, AliveCor, Champion Medical, Apervita, Eko Consulting Fees (e.g., advisory boards): Medtronic, Boston Scientific Contracted Research: St. Jude Medical Other: AliveCor and Eko- Mayo Clinic has licensed IP to AliveCor and Eko and I may benefit from its commercialization, but not when used for patients at Mayo Clinic Mahmut Gurol, MD, MSc States the following: Other: Research Support (Investigator Sponsored) Avid, Pfizer, Boston Scientific Michel Haissaguerre, MD Hereby states that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months Kevin Heist, MD, PhD States the following: Consulting Fees (e.g., advisory boards): Biotronik, Boston Scientific, Abbott, Pfizer Ownership Interest less than 5% (stocks, stock options, or other ownership interest excluding diversified mutual funds): Oracle Health (non-public startup) Rodney Horton, MD States the following: Consulting Fees (e.g., advisory boards): Boston Scientific, Biosense Webster, Abbott Elaine Hylek, MD, MPH States the following: Consulting Fees (e.g., advisory boards): Bistol Myers Squibb/Pfizer, Medtronic Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents (e.g., speakers’ bureaus):Boehringer Ingelheim, BMS/PFizer Contracted Research: Abbott, Janssen Pierre Jais, MD States the following: Consulting Fees (e.g., advisory boards): BSC, Farapulse Ownership Interest less than 5% (stocks, stock options, or other ownership interest excluding diversified mutual funds): Farapulse Jose Jalife, MD States the following: Hereby states that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months David Keane, MD, PhD States the following: Hereby states that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months Young-Hoon Kim, MD, PhD States the following: Hereby states that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months

5 Bradley Knight, MD States the following: Consulting Fees (e.g., advisory boards): BSCI, MDT, Abbott, Baylis, Biotronik Hans Kottkamp, MD States the following: Contracted Research: Kardium Ownership Interest less than 5% (stocks, stock options, or other ownership interest excluding diversified mutual funds):Kardium Karl-Heinz Kuck, MD States the following: Consulting Fees (e.g., advisory boards): Biosense Webster, Biotronik, Impulse Dynamics, Abott Vascular Dhanunjaya Lakkireddy, MD States the following: Consulting Fees (e.g., advisory boards): Janssen, Biotronik, Biosense Webster, Abbott Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents (e.g., speakers’ bureaus): Bristol Myers Squibb, Janssen Moussa Mansour, MD States the following: Consulting Fees (e.g., advisory boards): Abbott, Biosense Webster, Jonhson and Johnson, Boston Scientific, Janssen, Medtronic, Philips, Novartis, Sentre Heart Research Grants: Abbott, Biosense Webster, Jonhson and Johnson, Boston Scientific, Medtronic, Pfizer, Boehringer Ingelheim, Sentre Heart Equity: Affera, EPS Solutions, NewPace Ltd Francis Marchlinski, MD States the following: Consulting Fees (e.g., advisory boards): Abbott Laboratories/ St Jude Medical; Medtronic; Biosense Webster Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents (e.g., speakers’ bureaus): Fellows Lectures- Biotronik; Boston Scientific; Biosense Webster; Medtronic Nassir Marrouche, MD States the following: Consulting Fees (e.g., advisory boards): Abbott, Biotronik, Wavelet Health, Cardiac Design, Medtronics, Preventice, Vytronus, Biosense Webster, Marrek Inc, Boston Scientific Contracted Research: Abbott, Boston Scientific, GE Healthcare, Siemens, Biotronik, Vytronus, Biosense Webster Ownership Interest less than 5% (stocks, stock options, or other ownership interest excluding diversified mutual funds): Marrek Inc, Cardiac Design Gregory Michaud, MD States the following: Consulting Fees (e.g., advisory boards): Biosense Webster; Abbott Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents (e.g., speakers’ bureaus): Biosense-Webster, Abbott, Medtronic, Biotronik, Boston Scientific Damijan Miklavcic, DSc States the following: Consulting Fees (e.g., advisory boards): Medtronic Contracted Research: Medtronic Suneet Mittal, MD States the following: Hereby states that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months

6 Hiroshi Nakagawa, MD, PhD States the following: Consulting Fees (e.g., advisory boards): Biosense Webster, Inc., Boston Scientific, Inc., Japan Lifeline, KK, Fukuda Desnshi, KK, Affera, Inc. Contracted Research: Biosense Webster, Inc., Affera, Inc. Andrea Natale, MD States the following: Consulting Fees (e.g., advisory boards): Abbott, Biosense Webster, Medtronic, Biotronik, Boston Scientific, Baylis Petr Neuzil, MD, PhD Hereby states that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months Douglas Packer, MD States the following: Dr. D. Packer in the past 12 months has provided consulting services for Abbott $0, Biosense Webster $0, Inc., Biotronik <$5000, Boston Scientific $0, CardioFocus $0, Johnson & Johnson $0, MediaSphere Medical, LLC<$5000, Medtronic $0, St. Jude Medical $0, and Siemens $0, SigNum Preemptive Healthcare, Inc.$0, Spectrum Dynamics $0, and Thermedical $0. Dr. Packer receives research funding from the Abbott, Biosense Webster, Boston Scientific/EPT, CardioInsight, CardioFocus, Endosense, Hansen Medical, Medtronic, NIH, Robertson Foundation, St. Jude Medical, Siemens and Thermedical. Mayo Clinic and Drs. D. Packer and R. Robb have a financial interest in mapping technology. In accordance with the Bayh-Dole Act, this technology has been licensed to St. Jude Medical, and Mayo Clinic and Drs. Packer and Robb have received annual royalties greater than $10,000, the federal threshold for significant financial interest. Mayo Clinic and Dr. R. Robb have a financial interest in Analyze-AVW technology that may have been used to analyze some of the heart images in this research. In accordance with the Bayh-Dole Act, this technology has been licensed to commercial entities, and both Mayo Clinic and Dr. Robb have received royalties greater than $10,000, the federal threshold for significant financial interest. In addition, Mayo Clinic holds an equity position in the company to which the AVW technology has been licensed. Dr. Packer and Mayo Clinic jointly have equity in a privately held company, External Beam Ablation Medical Devices. Royalties from Wiley & Sons, Oxford, and St. Jude Medical. Eric Prystowsky, MD States the following: Consulting Fees (e.g., advisory boards): Medtronic, Cardionet Vivek Reddy, MD States the following: Consulting Fees (e.g., advisory boards): Abbott, Biosense Webster, Biotronik, Boston Scientific, Cardiofocus, Impulse Dynamics, Medtronic, Philips, Stimda, Thermedical Contracted Research: Abbott, Boston Scientific, Biosense Webster, Recor Medical Ownership Interest less than 5% (stocks, stock options, or other ownership interest excluding diversified mutual funds): Ablacon, Acutus, Affera, Apama Medical, Aquaheart, Atacor, Autonomix, Axon, Backbeat, BioSig, Cardionomic, CardioNXT / AFTx, Circa Scientific, Corvia Medical, East End Medical, EBR, EPD, Epix Therapeutics, EpiEP, Eximo, Farapulse, Fire1, Javelin, Keystone Heart, LuxCath, Medlumics, Middlepeak, Newpace, Nuvera, Sirona Medical, Valcare Ownership Interest greater than 5% (stocks, stock options, or other ownership interest excluding diversified mutual funds): Manual Surgical Sciences, Surecor, Vizaramed

7 Jeremy Ruskin, MD States the following: Consulting Fees/Advisory Boards (Self)): Acesion Pharma; Advanced Medical Education; Apple; Cala Health; Correvio; Hanover Medical; InCarda; Janssen; Lantheus Medical; LuxCath; Medtronic; Novartis; Pfizer Ownership Interest less than 5% (Self): Ablacor; Apple; Element Science; Gilead; Infobionic; NewPace; Portola Ownership Interest greater than 5% (Self): Celero Systems (stock options) Walid Saliba, MD States the following: Consulting Fees (e.g., advisory boards): Biosense Webster, Boston Scientific Jacqueline Saw, MD States the following: Consulting Fees (e.g., advisory boards): Boston Scientific, Abbot Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents (e.g., speakers’ bureaus): Boston Scientific, Abbott, AstraZeneca, Bayer, Sunovion Other: Research- CIHR. HSFC, UBC Division of Cardiology, Abbott, AstraZeneca, Servier Ulrich Schotten, MD, PhD States the following: Receipt of Intellectual Property Rights/Patent Holder1: Non-invasive characterization of AF Consulting Fees (e.g., advisory boards): EP Solutions, Roche. Contracted Research: EP Solutions, Roche. Ownership Interest greater than 5% (stocks, stock options, or other ownership interest excluding diversified mutual funds): YourRhythmics BV Daniel Singer, MD States the following: Consulting Fees (e.g., advisory boards): Boehringer Ingelheim, Bristol-Myers Squibb, Johnson and Johnson, Merck, Pfizer Contracted Research: Boehringer Ingelheim, Bristol-Myers Squibb Natalia Trayanova, PhD States the following: Hereby states that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months Mintu Turakhia, MD States the following: Salary: Veterans Health Administration, Stanford Consulting Fees (e.g., advisory boards): Medtronic, Abbott, Myokardia, J&J, Pfizer Contracted Research: Apple, Janssen, BMS/Pfizer Ownership Interest less than 5% (stocks, stock options, or other ownership interest excluding diversified mutual funds): AliveCor Albert Waldo, MD States the following: Consulting Fees (e.g., advisory boards): Cardiac Insight, Milestone Pharmaceuticals, Biosense Webster Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents (e.g., speakers’ bureaus): Pfizer, Bristol-Myers Squibb Paul Wang, MD States the following: Hereby states that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months

8 David Wilber, MD States the following: Royalty1: Elsevier Consulting Fees (e.g., advisory boards): Biosense, ACC Foundation Contracted Research: Biosense, Abbott, Atricure Roger Winkle, MD States the following: Contracted Research: Abbott Ownership Interest less than 5% (stocks, stock options, or other ownership interest excluding diversified mutual funds): Farapulse PLANNERS AND MANAGERS The PIM planners and managers have nothing to disclose. The Advanced Medical Education planners and managers have nothing to disclose.Disclosure of Unlabeled Use This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. DISCLAIMER Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. REQUEST FOR CREDIT If you wish to receive acknowledgment for completing this activity, please complete the evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID 14559. Upon registering and completing the activity evaluation, your certificate will be made available immediately. DISCLOSURE OF UNLABELED USE This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

9 DISCLAIMER Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. REQUEST FOR CREDIT If you wish to receive acknowledgment for completing this activity, please complete the evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID 13429. Upon registering and completing the activity evaluation, your certificate will be made available immediately.

10 AF Symposium 2020 Faculty Biographies Amin Al-Ahmad, MD Texas Cardiac Institute, Austin, TX Dr. Amin Al-Ahmad is a practicing EP and Partner at Texas Cardiac Arrhythmia (TCA). Prior to TCA, he served as faculty at Stanford University School of Medicine. He was an instructor at Tufts Medical School where he completed his residency and fellowships in general cardiology and cardiac electrophysiology. He is the recipient of several teaching excellence awards and is well published. Dr Al-Ahmad’s area of interest is ablation of atrial and ventricular and development of new technologies. Elad Anter, MD Beth Israel Deaconess Medical Center, Boston, MA Dr. Anter is director of Experimental Research Laboratory, associate director of Clinical Electrophysiology Laboratory and a staff cardiac electrophysiologist at Beth Israel Deaconess Medical Center. A Harvard Medical School instructor, he is also director of EP Innovation and Development at Harvard Clinical Research Institute, and a member of the Thorndike Electrophysiology Institute team. A specialist in complex ablations, Dr. Anter focuses on atrial fibrillation, ventricular tachycardia including arrhythmogenic right ventricular cardiomyopathy and premature ventricular contractions. He is particularly interested in the study and treatment of these arrhythmias in the population. Dr. Anter also specializes in implantable devices, including cardiac resynchronization therapies. A graduate of Hadassah Medical School at the Hebrew University in Israel, he completed a residency in internal medicine at Brigham and Women’s Hospital in Boston, and fellowships in general cardiology and cardiac electrophysiology at the Hospital of the University of Pennsylvania in Philadelphia. Timothy Betts, MD Oxford University Hospitals, Oxford, UK Dr. Timothy Betts is a Consultant Cardiologist and Clinical Lead for Cardiac Electrophysiology at Oxford University Hospitals NHS Foundation Trust. Research interests include emerging technologies and treatment strategies for atrial fibrillation and other arrhythmias. Work currently being undertaken on global left atrial mapping to guide ablation of persistent atrial fibrillation, ultrasound and CT-guided imaging of ablation lesions and the impact of power settings on the safety and efficacy of radiofrequency ablation. Dr. Betts’s other main research area is in cardiac resynchronisation therapy to treat heart failure, with a particular interest in the electrophysiological and functional benefits of LV endocardial pacing. Lucas Boersma, MD St. Antonius Hospital, Nieuwegein, Netherlands Dr. Lucas Boersma is an electrophysiologist at St. Antonius Hospital in Nieuwegein, Netherlands. Since 2017, Dr. Boersma has also been a professor at the AMC in Amsterdam, chair: innovative trans-catheter treatments for cardiac arrhythmias Hugh Calkins, MD Johns Hopkins Hospital, Baltimore, MD Dr. Calkins, Director of the Electrophysiology Laboratory and Arrhythmia Service at Johns Hopkins Hospital and The Nicholas J. Fortuin M.D. Professor of Cardiology, is internationally recognized as an expert on catheter ablation, atrial fibrillation, syncope, and arrhythmia management. Dr. Calkins has published more than 600 articles and book chapters on a large variety of cardiac arrhythmias. His research has focused predominantly on catheter ablation, atrial fibrillation, syncope, and arrhythmogenic right ventricular dysplasia. Dr. Calkins has also written extensively on most aspects of heart rhythm disorders and their treatment. He was the lead author on the 2007, 2012, and 2017 Consensus Document on Catheter and Surgical Ablation of Atrial Fibrillation. He is a past President of the Heart Rhythm Society.

11 A. John Camm, MD St. George’s Medical Centre, London, UK John Camm is Professor of Clinical Cardiology at St George’s University of London. His interests include cardiac arrhythmias, atrial fibrillation, stroke prevention, anticoagulation, clinical cardiac electrophysiology, cardiac pacemakers, and risk stratification in post-, heart failure, atrial fibrillation and cardiomyopathy patients. Professor Camm is a fellow of the European Society of Cardiology, and the European Heart Rhythm Association. He is president of the Arrhythmia Alliance and Immediate Past President of the European Heart Rhythm Association the, founder and trustee of the Atrial Fibrillation Association and trustee of the Drug Safety Research Unit. Professor Camm is Editor-in-Chief of the European Heart Journal Case Reports, Editor of European Heart Journal, immediate past Editor-in-Chief of EP Europace, He is also Editor of the European Heart Journal, European Society of Cardiology Textbook of Cardiovascular Medicine (CardioMed). Larry Chinitz, MD NYU Langone Medical Center, New York, NY Dr. Larry Chinitz serves as the Clinical Director in cardiology at NYU Langone Health. He graduated from New York University in New York, and completed his residency and fellowship at New York University. Dr. Chinitz is an internationally renowned expert in the management of heart rhythm disorders. He established NYU Langone’s Clinical Cardiac Electrophysiology program and the Heart Rhythm Center to provide state-of-the-art cardiac rhythm management of atrial and ventricular arrhythmias. His current research focuses on the development of novel technology for use in catheter ablative therapies, investigation of neuro stimulation and pharmacotherapy to help regulate irregular heartbeats, and other innovative treatments for patients at risk for sudden cardiac death. In February 2014, Dr. Chinitz lead a team of NYU Langone specialists in implanting—for the first time in the United States—the bullet-sized Micra™ Transcatheter Pacing System, the world’s smallest leadless cardiac pacemaker. Stuart Connolly, MD McMaster University, Hamilton, Ontario, Canada Stuart J. Connolly is a Professor of Medicine at McMaster University in Ontario and a Cardiac Electrophysiologist at Hamilton Health Sciences, Ontario. Dr. Connolly holds a Masters degree from Fordham University, New York, and an MD from McGill University in Montreal. He received his specialist training in cardiology at the University of Toronto and at Stanford University. Dr. Connolly became a faculty member at McMaster University in 1983 and was awarded a full professorship in 1994. As well as being an active clinical cardiologist, Dr. Connolly held the position of Director of the Division of Cardiology 2005-2015. He was also appointed as the inaugural holder of the Salim Yusuf Chair in Cardiology at McMaster University during that time. Dr. Connolly has published more than 410 scientific articles in the field and is currently a member of the editorial boards for a number of prominent Cardiology journals, including Heart, the Journal of Pacing and Electrophysiology, and Journal of the American College of Cardiology. Dr. Connolly’s main research interests are focused on the evaluation of treatments for heart rhythm disorders. His academic career has been largely devoted to the design and execution of controlled clinical trials in this area. John Day, MD Intermountain Heart Institute, Murray, UT Dr. John Day graduated from medical school at Johns Hopkins University. He did his residency in internal medicine, cardiology, and cardiac electrophysiology fellowship training at Stanford University. Dr. Day is an electrophysiologist at the Intermountain Medical Center Heart Institute in Salt Lake City, Utah. He previously served as president of the Heart Rhythm Society and currently serves the Utah Governor of the American College of Cardiology. He is recognized as an international thought leader on atrial fibrillation management. Dr. Day is board certified in cardiology, and cardiac electrophysiology. He has published more than 100 manuscripts, abstracts, and book chapters and regularly lectures both nationally and internationally on heart rhythm disorders. Dr. Day is the former editor-in-chief of the Journal of Innovations in Cardiac Rhythm Management. In 2017 Dr. Day published The Longevity Plan: Seven Life-Transforming Lessons from Ancient China, with Harper Collins as publisher. The Longevity Plan was an Amazon number one best seller and was named best books of 2017 by the Huffington Post and won the Nautilus Book Award Gold Medal for the best book of 2017.

12 Isabel Deisenhofer, MD German Heart Centre Munich, Munich, Germany Prof. Dr. Deisenhofer completed her medical studies as a scholar of the Scholarship for Highly Gifted Students of the Bavarian Government, her preclinical medical studies at Ludwig-Maximillians-Universität München and her clinical studies at Technischen Universität München. Both her internship and residency were completed in cardiology at the German Heart Center Munich. With a grant from the German Research Society, Prof. Dr. Deisenhofer joined Prof. Michel Haissaguerre’s research group at Hôpital Cardiologique du Haut-Lévêque, Bordeaux-Pessac, Université de Bordeaux, France; and then returned to the German Heart Center, where she completed a fellowship in electrophysiology. Following this, she served as a cardiology professor (2007-2014) at Technischen Universität München. Since 2007, Prof. Dr. Deisenhofer has served as head of the Section for Electrophysiology and, since 2014, the head of the Department for Electrophysiology at the German Heart Center. Thomas Deneke, MD Cardiovascular Center Bad Neustadt, Germany Prof. Deneke is director of the clinic for Cardiac Electrophysiology at the Heart Center Campus Bad Neustadt, focusing on catheter ablation of complex atrial and ventricular arrhythmias. This includes evaluating multiple novel ablation devices and techniques to treat atrial fibrillation and LAA occlusion/ligation program using different devices and technologies. The center is involved in many single and multicenter studies in the field of arrhythmia treatment and catheter ablation. The members of the EP team have been actively publishing their clinical science findings for several years. In addition, Prof. Deneke is a teacher for rhythmology and cardiology at the Ruhr-University Bochum and is involved in numerous educational sessions for young and experienced electrophysiologists throughout Germany and Europe. Aneesh Deoras, BS, MSE U.S. Food & Drug Administration, Silver Spring, MD Aneesh Deoras is an electrical engineer in the FDA’s Office of Cardiovascular Devices, Center for Devices and Radiological Health. He is responsible for the review of new medical devices, primarily ablation catheters and electroanatomic mapping systems. He serves as a subject matter expert in electromagnetic compatibility and supports multiple digital health innovation pathways. He is a graduate of Penn State University (BS, Electrical Engineering) and the University of Pennsylvania (MSE, Bioengineering). Tom De Potter, MD OLV Hospital, Aalst, Belgium Dr. De Potter graduated in 2001 from the University of Leuven in Belgium and trained as a cardiologist in Aalst and Ghent University until 2007, and as an electrophysiologist in Barcelona and Hamburg until 2009. Since 2009, he joined the Cardiovascular Center Aalst, Belgium, where he currently serves as associate director, clinically active within the arrhythmia unit of the department. He has focused on developing a multimodality imaging approach to support complex arrhythmia treatment, using and combining existing and experimental technologies such as intracardiac echography, 3D mapping/ navigation and rotational angiography. This has resulted in the arrhythmia unit becoming one of few European training centers for ventricular tachycardia ablation and the only center worldwide for training physicians on a minimal radiation workflow for atrial fibrillation ablation. As a spin-off, this imaging expertise has been translated to the structural heart program that has also resulted in the arrhythmia unit being selected as a training site for LAA closure and a study site for existing and novel devices for LAA closure.

13 Luigi Di Biase, MD, PhD Albert Einstein College of Medicine, Bronx, NY Dr. Luigi Di Biase is Section Head of Electrophysiology, Director of Arrhythmia Services, and Professor of Medicine (Cardiology) at Einstein/Montefiore. In addition, he serves as Senior Researcher at the Texas Cardiac Arrhythmia Institute at St. David’s Medical Center, Austin, Texas. Improving patient care is the heart of Dr. Di Biase’s mission. He believes that this is possible through dedicated clinical practice associated to cutting-edge clinical research. Dr. Di Biase’s research focuses on cardiology and electrophysiology with specific emphasis on catheter ablation of atrial fibrillation and ventricular arrhythmias performed either manually or with robotic catheter navigation. Additionally, his research focuses on heart failure, particularly cases treated with cardiac resynchronization therapy devices. He is a 2000 graduate (summa cum laude) of the medical school and a 2004 graduate (summa cum laude) of the cardiology residency program at the University of Bari, Bari, Italy. In 2006, he completed a second-level master degree in Electrophysiology and Pacing (summa cum laude) at the University of Insubria, Varese, Italy. Dr. Di Biase is the author of more than 400 publications in indexed journals, about 500 abstracts, and 16 electrophysiology book chapters. He has presented at numerous national and international conferences as an invited speaker. Jun Dong, MD U.S. Food & Drug Administration, Silver Spring, MD Dr. Jun Dong is a medical officer and senior clinical reviewer at the Center for Devices and Radiological Health (CDRH), US Food and Drug Administration (FDA). He serves as the primary medical officer for the atrial fibrillation program in the CDRH’s Office of Cardiovascular Devices. He provides scientific and clinical leadership in the area of cardiac electrophysiology devices and procedures, with particular emphasis on the evaluation of mapping and ablation devices for the treatment of arrhythmias. A significant part of his work involves collaborating with device manufacturers and investigators to design clinical studies that are robust, efficient, and tailored to the technology and the medical need being addressed. Dr. Dong is also an Adjunct Assistant Professor of Medicine at the Johns Hopkins Medicine/Cardiology. He earned his medical degree at the Chongqing Medical University in Chongqing, China. He completed his clinical trainings in Internal Medicine and Cardiology at the Second Teaching Hospital of Chongqing Medical University. He received further training in cardiac electrophysiology at the German Heart Center Munich and a doctorate from the Technische Universtät München (Technical University of Munich) in Munich, Germany. He then completed a postdoctoral clinical research fellowship in cardiac electrophysiology under Hugh Calkins, MD with emphasis on catheter ablation of atrial fibrillation and image-guided catheter ablation of complex arrhythmias at the Johns Hopkins Electrophysiology Laboratory before joining the FDA in 2007. Patrick Ellinor, MD, PhD Massachusetts General Hospital, Boston, MA Dr. Ellinor, Professor of Medicine at Harvard Medical School, is director of Cardiac Arrhythmia Service, Massachusetts General Hospital (MGH), and an associate member at the Broad Institute. Dr. Ellinor’s research work has focused on identifying the molecular basis of atrial fibrillation. His research laboratories are located in the Cardiovascular Research Center at MGH and at the Broad Institute of Harvard and MIT. Dr. Ellinor currently helps lead the AF and Gen Consortium, an international group of investigators studying the genetics of atrial fibrillation. Over the past 15 years, he has been continuously funded by the NIH, has received an Established Investigator Award from the AHA, and is a principal investigator on a Transatlantic Research Network sponsored by the Foundation Leducq. Dr. Ellinor is a member of the American Heart Association, the Heart Rhythm Society and the American Society of Clinical Investigation. Andrew Farb, MD U.S. Food & Drug Administration, Silver Spring, MD Andrew Farb, MD is a medical officer and senior reviewer in the Division of Cardiovascular Devices at FDA’s Center for Devices and Radiological Health (CDRH). He is a graduate of Dartmouth College (BA) and Cornell University Medical College (MD). He completed an internship and residency in internal medicine, a one-year residency in anatomic pathology, and a fellowship in clinical cardiology at The New York Hospital – Cornell University Medical Center. Following a fellowship in cardiovascular pathology at The Armed Forces Institute of Pathology (AFIP), he served as a staff cardiovascular pathologist at AFIP with research interests in and publications on coronary atherosclerosis and mechanisms of thrombosis, coronary artery interventions, and structural heart disease. He joined the FDA in 2004, where he has concentrated on clinical study development for interventional cardiology, structural heart, and peripheral vascular devices.

14 John Foran, MD Royal Brompton Hospital, London, UK Dr John Foran qualified in 1988 at St George’s Hospital (University of London) and specialised in cardiovascular medicine, training in aspects in both adult and paediatric cardiology. This training incorporated time at a number of tertiary centres, including The Brook, St George’s, Great Ormond Street Hospital for Children, King’s College Hospital and the Manchester Heart Centre. He completed his specialist training in 1999 and undertook his first consultant post in 2000. Dr Foran is currently a consultant cardiologist at Royal Brompton Hospital and also St Helier University Hospital (Surrey).Dr. Foran specialises in interventional cardiology including: coronary angioplasty, stent implantation, management of heart rate, rhythm disorders (catheter ablation and pacemaker/device implantation), structural heart disease (including left atrial appendage closure techniques). He has over 20 years of experience in coronary angioplasty (performing his first procedure in 1990) and catheter ablation (performing his first procedure in 1991). In 2003, Dr Foran pioneered LA appendage occlusion – a key-hole interventional technique used for stroke prevention in patients. Dr Foran’s research interests are largely focused on new and emerging therapies for stroke prevention in atrial fibrillation. He has travelled internationally to speak at many conferences and for his clinical work. Paul Friedman, MD Mayo Clinic, Rochester, MN Dr. Paul Friedman is a Professor of Medicine and Chair of the Department of Cardiovascular Medicine at Mayo Clinic, Rochester, Minnesota. He is ABIM board certified in cardiovascular medicine and cardiac electrophysiology, and is an active participant in the MOC process. Previously, Dr. Friedman served as Director of the Cardiac Implantable Device Lab, Mayo Clinic. He is a trained electrical engineer, with deep experience in innovation (> 40 patents issued, named Minnesota Top Inventor), and scientific research (> 250 scientific original publications). He is a committed educator, serving as a director for 5 national and international meetings, editor of 7 textbooks, and author of over 60 book chapters. He is a frequent visiting professor and lecturer at educational meetings. Dr. Friedman received his BA in Plan II liberal arts and BS in Electrical Engineering from the University of Texas at Austin. He received his medical degree from Stanford University, and trained in internal medicine at the University of Washington, Seattle (internship) and Stanford University. He trained in cardiovascular medicine and cardiac electrophysiology at Mayo Clinic, Rochester, MN. Interests • Atrial fibrillation management, including medications, remote monitoring, medications, ablation, and left atrial appendage closure • Ventricular arrhythmia management (PVCs, VT) • Medical and ablative management of SVTs • Complex cardiac ablation, atrial and ventricular arrhythmia • Cardiac device insertion, including leadless pacemaker, His bundle pacing, and subcutaneous defibrillator • Interventional procedures (venoplasty, snaring) for pacemaker, ICD, and resynchronization device placement • Percutaneous epicardial access for complex ablation and appendage closure • Implantable device extraction • Artificial intelligence in medicine • Remote monitoring Philippe Genereux, MD Morristown Medical Center, Morristown, NJ Dr. Genereux is the Director of Structural Heart Disease Program at Gagnon Cardiovascular Institute, Morristown Medical Center in Morristown, New Jersey.

15 Benedict Glover, MD Sunnybrook Health Science Ctr, Toronto, Ontario Canada Dr. Ben Glover, cardiac electrophysiologist and research scientist at the Schulich Heart Centre, is a rising star in the clinical and experimental cardiology community. Along with publishing in the top cardiology journals and co-authoring two books, he is an associate professor of cardiology at the University of Toronto, and is involved in several prominent decision-making groups - including the Canadian Cardiovascular Society, Canadian Heart Rhythm Society and Cardiac Arrhythmia Network of Canada (CANet). With expertise recognized on a national and international scale, Dr. Glover is also a member of the Sunnybrook’s electrophysiology (EP) team, led by Dr. Eugene Crystal. They are responsible for performing more than 10 percent of all EP procedures in the province each year. Mahmut Gurol, MD, MSc Massachusetts General Hospital, Boston, MA Dr. Gurol, a vascular neurologist and NIH-funded researcher at Massachusetts General Hospital and Harvard Medical School, is an international expert on cerebral small vessel diseases of the elderly such as cerebral amyloid angiopathy, conditions that increase the risk of both hemorrhagic and ischemic cerebral events in affected individuals. He uses advanced neuroimaging techniques to clarify the molecular and physiologic mechanisms of these microangiopathies and develop methods to stratify hemorrhagic risk. Dr. Gurol’s clinical focus is stroke prevention in the high-risk patient, i.e. patients with a hemorrhage prone cerebral pathology as well as concomitant high embolic risk such as atrial fibrillation. Michel Haissaguerre, MD Central Hospital, Bordeaux, France Professor Haïssaguerre teaches at the Hôpital Cardiologique du Haut-Lévêque, Bordeaux-Pessac, and is the director of the Electrophysiology and Heart Modeling Institute LIRYC. He has an outstanding national and international scientific reputation. His scientific and clinical work focuses on cardiovascular electrophysiology, particularly on cardiac fibrillation. He is best known for his remarkable contributions in the area of atrial fibrillation ablation. He was the first to detect the importance of pulmonary vein triggers and drivers in the genesis of atrial fibrillation. In addition, he was first to propose the technique of pulmonary vein isolation, which underlies current methods used throughout the world for atrial fibrillation cure. His team has also demonstrated that Purkinje cells were the main triggers of human ventricular fibrillation, with or without heart disease. Kevin Heist, MD, PhD Massachusetts General Hospital, Boston, MA Dr. Heist is an Associate Professor of Medicine at Harvard Medical School and an Associate Physician in Cardiology and Cardiac Electrophysiology at MGH. He is the Program Director for the Clinical Cardiac Electrophysiology Fellowship at MGH. Dr. Heist received his MD and PhD degrees from Stanford University School of Medicine, and received an MMSc degree from the Harvard/MIT Health Sciences Training Program. He completed his Internal Medicine Residency at UC San Francisco, and he then completed Fellowships in both and Clinical Cardiac Electrophysiology at Massachusetts General Hospital. His clinical and research interests focus on catheter ablation of cardiac arrhythmias including atrial fibrillation (AF), supraventricular tachycardia (SVT) and ventricular tachycardia (VT), as well as implantation and follow-up of cardiac device therapy including pacemakers, implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy (CRT) devices. He has published over 150 papers on these topics, and is frequently invited to give educational lectures on these subjects.

16 Rodney Horton, MD Texas Cardiac Arrhythmia Institute, Austin, TX Now among the leading physicians in his field, Dr. Rodney Horton’s accomplished career in electrophysiology can be traced back to a difficult case he experienced as a young doctor during his internship. It was a patient who had been experiencing frequent, unexplained black outs. The cause eluded the medical team until, finally, heart tracing revealed the problem to be a subtle rhythm disturbance. Frustrated by the difficulty of the diagnosis, Dr. Horton learned all he could about electrophysiology. It would become his specialty, and the man with the difficult diagnosis would become his first ablation patient. Dr. Horton earned his medical degree at the University of Texas Southwestern Medical School in Dallas, where he also completed his fellowship in electrophysiology. Also at UT Southwestern Medical School, he has served as an Assistant Professor in Internal Medicine, Division of Cardiology. He is a recipient of the Southwestern Medical Foundation Scholarship for Academic Excellence and the Rotary International Fellowship for Study Abroad at the University of Heidelberg, Germany, in the field of medicine. Dr. Horton also presented as a guest lecturer at the prestigious Boston Atrial Fibrillation Symposium in 2006. At the top the list of his most important accomplishments, though, Dr. Horton places all the patients he has helped during his career. John Hummel, MD Ohio State University Medical Center, Columbus, OH Dr. Hummel earned his medical degree at the University of Virginia School of Medicine in Charlottesville, Virginia. He completed his residency in internal medicine and fellowships in cardiovascular medicine and cardiac electrophysiology at The Johns Hopkins Hospital in Baltimore, MD. In addition, Dr. Hummel completed a visiting fellowship in cardiac electrophysiology at the University of Michigan in Ann Arbor, Michigan where he also served as an assistant professor of medicine. He has published a number of abstracts and peer-reviewed journal articles, as well as a textbook in electrophysiology. Dr. Hummel frequently speaks to national and international audiences on various topics in the field of cardiovascular electrophysiology. Elaine Hylek, MD, MPH Boston University Medical Center, Boston, MA Dr. Hylek is a Professor of Medicine and Director of the Thrombosis and Anticoagulation Service at Boston University Medical Center. She earned her medical degree at the University of Pittsburgh and received her internal medicine training at Massachusetts General Hospital and Harvard Medical School. Research areas include arterial (stroke) and venous thrombosis, anticoagulant therapies, and atrial fibrillation. Recent investigations have included the role of biomarkers in atrial fibrillation related stroke, factors associated with major hemorrhage and antithrombotic therapy, and the efficacy and safety of novel oral anticoagulant drugs. She has served on the executive steering committees for international clinical trials and national registries, event adjudication committees, and data safety monitoring boards. She is a section editor for Thrombosis and Haemostasis, and a member of the International Society of Thrombosis and Haemostasis Executive Committee for World Thrombosis Day. Pierre Jais, MD Central Hospital, Bordeaux, France Pierre Jaïs, MD a Professor at the Cardiology Hospital, Pessac, France, working with Michel Haïssaguerre in the Rhythmolgy & Cardiac Stimulation Department, co-manages the LIRYC Institute (Electrophysiology and Heart Modeling Institute) and the MUSIC EQUIPEX; both aim to improve knowledge and treatments of electrical dysfunctions of the heart with an extra focus on imaging for MUSIC. Dr. Jaïs is a regular contributor to national and international symposia and has written more than 400 articles, mainly on electrophysiology and RF catheter ablation, particularly focusing on atrial arrhythmias. He is currently working on catheter ablation for atrial and ventricular arrhythmias with special focus on advanced imaging integration and modeling to guide ablation procedures.

17 Jose Jalife, MD University of Michigan, Ann Arbor, MI Dr. Jalife is the Cyrus and Jane Farrehi Professor of Cardiovascular Research; professor of internal medicine and molecular and integrative physiology, University of Michigan Medical School; and co-director of the University of Michigan Center for Arrhythmia Research. He completed his MD at the National University of Mexico in 1972. After clinical training in Spain, he conducted postdoctoral research in pharmacology at the National Institute of Cardiology in Mexico, Upstate Medical University, and at the Masonic Medical Research Laboratory in Utica, New York. He joined the Department of Pharmacology at Upstate Medical University as a member of the faculty in 1980 and became chairman of the department in 1988. He has received the 2009 Distinguished Scientist Award from the Heart Rhythm Society, as well as the 2010 Mirowski Award for Excellence in Clinical Cardiology and Electrophysiology. Jerome Kalifa, MD, PhD Brown University, Providence, RI Both basic scientist and clinical electrophysiologist, Dr. Jérôme Kalifa is based in the USA and currently Faculty at Brown University, Rhode Island, USA. Dr. Kalifa dedicated about two decades to translational and clinical research in cardiac electrophysiology. He is a seasoned speaker, chairman and reviewer for multiple cardiac electrophysiology journals and conferences. His research effort has focused on understanding atrial fibrillation mechanisms. Dr. Kalifa is the co-founder of Volta Medical, a company dedicated to developing machine learning solutions for interventional cardiac electrophysiology. David Keane, MD, PhD St. Vincent’s University Hospital, Dublin, Ireland Professor Keane is Director of the Cardiac Arrhythmia Service at St. Vincent’s University Hospital, Dublin. Professor Keane received his training at Guy’s Hospital, London, Erasmus University Hospital, Rotterdam, The Netherlands and Massachusetts General Hospital, Boston Massachusetts, where he subsequently became Director Interventional Cardiac Electrophysiology. He is internationally recognized for his expertise in catheter ablation for cardiac arrhythmia, focusing on atrial fibrillation. He is a member of the Heart Rhythm Society, European Cardiac Arrhythmia Society, European Heart Rhythm Association, European Society of Cardiology, Royal College of Physicians of Ireland, Royal Society of Medicine, Irish Cardiac Society and is Chair of the EP Subgroup of the Irish Cardiac Society. Young-Hoon Kim, MD, PhD Korea University Medical Center, Seoul, Korea Dr. Kim is a Professor of Medicine and Director of the Cardiac Arrhythmia Center at Korea University, Seoul, Korea. He completed his postgraduate training in internal medicine at Korea University Medical Center, fellowship training in cardiology and cardiac electrophysiology at Korea University, and research fellowship training at Cedars-Sinai Medical Center, Los Angeles, Dr. Kim joined the faculty in the Department of Medicine-Cardiology at the University of Korea, where he established the training and research program in clinical cardiac electrophysiology. He has participated in many professional societies’ scientific- program development and consensus documents. His principal research interests are catheter ablation of atrial fibrillation and ventricular tachycardia, and mapping of underlying mechanisms of various tachyarrhythmias. Bradley Knight, MD Northwestern University, Chicago, IL As medical director of cardiac electrophysiology at Northwestern Memorial Hospital since November 2009, Dr. Knight remains clinically active with a broad range of clinical and research interests in the field of heart rhythm disorders. These interests range from catheter ablation for complex arrhythmias, such as atrial fibrillation, to fundamental issues related to the basic mechanisms of various types of heart rhythm disorders, and the use of imaging in the electrophysiology laboratory to guide ablation procedures and device implantation. He is involved in several multicenter clinical trials that are evaluating novel ablation tools and implantable devices, including a totally subcutaneous implantable defibrillator. He has coauthored more than 250 scientific papers and is on the editorial board of several high-impact medical journals.

18 Jacob Koruth, MD Mount Sinai Medical Center, New York, NY Dr. Koruth received his cardiac electrophysiology training at Massachusetts General Hospital and then completed a research fellowship at Mt. Sinai Medical Center, New York. He completed his medical training at Christian Medical College, Punjab, India. He is currently an Assistant Professor of Medicine at the Leona M. And Harry B. Helmsley Electrophysiology center at Mt. Sinai Medical Center, New York. His clinical practice and range of interest encompasses all aspects of clinical electrophysiology with a particular focus in catheter ablation. He is the Director of the Experimental laboratory at Mt. Sinai Medical Center where he works to explore new approaches to catheter ablation and mapping. Hans Kottkamp, MD Sana Hospitals Duesseldorf, Duesseldorf, Germany From 1998 to 2006, Prof. Kottkamp headed the Department of Electrophysiology at the Heart Center Leipzig in Germany. Since 2006, he has served as head of Department of Electrophysiology at Hirslanden Hospital in Zurich, Switzerland. Prof. Kottkamp’s research focuses on catheter ablation of supraventricular and ventricular arrhythmias with special emphasis on ablation of atrial fibrillation. He has been published in more than 150 international journals and monographs, and serves on the Editorial Board of the Journal of Cardiovascular Electrophysiology and as a Section Editor of the Journal of the American College of Cardiology. In his clinical work, Prof. Kottkamp is dealing with all aspects of interventional cardiac electrophysiology, from catheter ablation to implantation of PM, ICD and CRT. Karl-Heinz Kuck, MD St. George’s Hospital, Hamburg, Germany Prof Karl-Heinz Kuck is currently the head of the Department of Cardiology at the Asklepios Klinik St. Georg in Hamburg, Germany. His main scientific interest since the 1980s has been clinical electrophysiology, eventually focusing on catheter ablation of various types of atrial, atrioventricular and ventricular tachyarrhythmia. He has been the Principal Investigator of a number of large randomized controlled trials, among them CASH, CAT, DINAMIT, VTACH and FIRE AND ICE. In recent years, Prof Kuck has also become actively involved in the field of catheter-based treatment of valvular heart diseases. His scientific interests are reflected (as of August 2018) in more than 700 papers he has authored or co-authored. Prof Kuck has served as a Board Member of the European Heart Rhythm Association (EHRA) and served as EHRA President. Dhanunjaya Lakkireddy, MD University of Kansas, Kansas City, KS Dr. Dhanunjaya Lakkireddy is a board-certified, fellowship-trained cardiologist specializing in electrophysiology and the Medical Director for the Kansas City Heart Rhythm Institute at HCA Midwest Health. Dr. Lakkireddy is affiliated with the HCA Midwest Health network of hospitals located throughout the Kansas City, Mo and Overland Park, Kan. metro areas. With more than 15 years of experience, he has specialized clinical expertise and interests in electrophysiology, complex arrhythmia management (atrial fibrillation, atrial flutter, ventricular tachycardia, supraventricular tachycardia), heart ablation, left atrial appendage closure; ablation, pacemaker and other device implantation and management, cardiac resynchronization therapy& pulmonary artery pressure sensors in heart failure, premature ventricular contractions, syncope, adult congenital and inherited cardiac rhythm disorders (Long QT, hypertrophic cardiomyopathy, arrhythmogenic right ventricular dysplasia, Brugada syndrome) and myocarditis. Currently professor of medicine in the department of internal medicine at the University of Missouri Columbia, and a renowned leader in electrophysiology research and education. Dr. Lakkireddy is the recipient of numerous professional honors and awards, including a Prevention Magazine Integrative Medicine Award, Ingram’s Heroes in Health Care Award, Professional of the Year by KC Asian Chamber of Commerce and Researcher of the Year by OGKTMA. Many of his accolades have centered on his extensive clinical research activity. He continues to serve as the principal investigator for clinical trials and studies around the world. He has published more than 360 articles on his cutting edge research in the field of electrophysiology. Additionally, Dr. Lakkireddy serves as Editor-in-Chief for the Journal of Atrial Fibrillation; Deputy Editor for JICE and a Editorial Board member and reviewer for more than 30 scientific publications including the American Heart Journal, American Journal of Cardiology, Clinical Cardiology, Heart Rhythm Journal, and the Journal of Interventional Cardiac Electrophysiology. He was the former governor of the Kansas American College of Cardiology. He is very active in the cardiovascular professional societies. He is the Chairman of the ACC Electrophysiology Council and HRS Global Ambassadors Committee and is the member of Program Committee in Heart Rhythm Society. He is a featured speaker in several national and international cardiovascular symposia.

19 Monica Lo, MD Arkansas Heart Hospital, Little Rock, AR Born in Taiwan, Dr. Lo moved with her family to Texas when she was 12 years old. She graduated with honors from Rice University, and then received her medical degree at the University of Texas Southwestern Medical Center in Dallas, where she was inducted into the Alpha Omega Alpha Honor Medical Society. She stayed at UT Southwestern to complete her internal medicine residency and fellowships in cardiology and clinical cardiac electrophysiology. She has been awarded the American Heart Association Women in Cardiology Trainee Award for Excellence. An active member of the American College of Cardiology and the Heart Rhythm Society, Dr. Lo has given several talks at these organizations’ national meetings. She moved to Little Rock, Arkansas, to establish the complex ablation program at the Arkansas Heart Hospital. It has become one of the busiest centers in the country in terms of patient volume and clinical research. Srijoy Mahapatra, MD University of MN Medical School, Minneapolis, MN As Chief Strategy Officer, Srijoy leads general strategy, planning, and business partnerships throughout the M-Health system which includes 12 hospitals. As the Assistant Dean, Srijoy works in the medical school to create novel clinical programs to treat unmet needs to help patients live longer, healthier lives. He serves on the Minnesota Rare Disease council. Prior to Fairview, he held several roles at Abbott Labs and St. Jude Medical, where he led worldwide clinical trials in cardiology, structural heart, and electrophysiology. Srijoy was an Assistant Professor of Medicine and Biomedical Engineering at the University of Virginia as well as Head Team Cardiologist for NCAA student-athletes. He continues to see patients as a consulting cardiologist to the National Basketball Players Association, NFL, and NHL. Srijoy has been involved in several startup companies, holds 11 patents, and has had his work appear in more than 150 publications. He holds a bachelor’s degree in electrical engineering, Master of Business Administration, and certification in artificial intelligence from Massachusetts Institute of Technology as well as a Doctor of Medicine degree from Tufts University. Srijoy completed a Cardiology & Electrophysiology fellowship at the Mayo Clinic and advanced training in complex ablation at Haut Levaque in Bordeaux, France, and INCOR in Sao Paulo, Brazil. Kevin Makati, MD St. Joseph’s Hospital, Tampa, FL Kevin J. Makati, MD, graduated from the University of School of Medicine in Farmington, Connecticut and completed his internal medicine residency at Washington University School of Medicine, Barnes-Jewish Hospital, in St. Louis, Missouri. He completed his fellowship training in cardiology and cardiac electrophysiology and pacing at Tufts University Medical Center in Boston, Massachusetts. He is currently an assistant professor at the University of South Florida, Department of Cardiology. In addition to clinical practice, Dr. Makati chairs the Rhythm Section for BayCare Health Systems which serves to coordinate healthcare spanning 15 non for profit hospitals, 17 outpatient clinics and over 2800 physicians. His research interests include hybrid therapies, multidisciplinary collaboration, ultra-sensitive mapping, and arrhythmia mechanisms. Dr. Makati has served on multiple advisory boards, steering committees, as well as international consortiums for hybrid therapies. He is an invited reviewer and on editorial boards for peer reviewed journals. Moussa Mansour, MD Massachusetts General Hospital, Boston, MA Dr. Mansour is an Associate Professor in Medicine at Harvard Medical School. He is also Director of the Atrial Fibrillation Program and the inaugural incumbent of the Jeremy Ruskin and Dan Starks Endowed Chair in Cardiology at the Massachusetts General Hospital. He is an active clinical consultant in all aspects of heart rhythm disorders, including atrial fibrillation, ventricular tachycardia, supraventricular tachycardia, bradycardia and other abnormal rhythms. Dr. Mansour performs a large number of catheter ablation procedures, and implants pacemakers and defibrillators to treat different arrhythmias. He has published extensively in the field of cardiac arrhythmia, specifically the area of atrial fibrillation. Additionally, Dr. Mansour is involved in cutting-edge research and currently participating in the development of new catheters for the treatment of atrial fibrillation.

20 Francis Marchlinski, MD University of Pennsylvania, Philadelphia, PA Francis Marchlinski MD FACC, FAHA, FHRS. Dr. Marchlinski is the Richard T and Angela Clark President’s Distinguished Professor of Medicine at the Perelman School of Medicine at the University of Pennsylvania, the Director of Electrophysiology, University of Pennsylvania Health Care System and the Director of the Electrophysiology Laboratory at the Hospital of the University of Pennsylvania. Dr. Marchlinski is a graduate of the University of Pennsylvania Medical School. He completed his postdoctoral internal medicine residency and cardiology/electrophysiology fellowship training at the Hospital of the University of Pennsylvania. For over thirty years Dr. Marchlinski has remained at the cutting edge of cardiac rhythm management. He has authored or co-authored over 450 original scientific articles and over 200 book chapters/reviews/editorials on a variety of topics in cardiac electrophysiology. His EP team at Penn has worked to successfully improve localizing and ablation techniques for the treatment of both atrial fibrillation and ventricular tachycardia and optimize device therapy for treating heart failure and preventing sudden cardiac death. Dr. Marchlinski has served on the International Heart Rhythm Society Committee to establish guidelines for the treatment of atrial fibrillation and ventricular tachycardia using catheter ablation techniques. He has been the recipient of the Luigi Mastroianni Clinical Innovator Award, the Venice Arrhythmia Distinguished Scientist Award and the ACTS Distinguished Investigator Award – Career Achievement –Translation from Early Clinical Use to Applicability for Widespread Clinical Practice. Dr. Marchlinski is on the editorial board of ‘Circulation, Arrhythmias and Electrophysiology’, ‘American Journal of Cardiology, ‘Heart Rhythm Journal’, ‘Journal of Cardiovascular Electrophysiology’, ‘Journal of Interventional Cardiac Electrophysiology’ and ‘JACC- Electrophysiology’ and is the Arrhythmia Section Editor for ‘Journal of the American College of Cardiology’. Dr. Marchlinski has organized and directed multiple fellowship training courses, regional and International EP symposia and has received numerous teaching awards at the University of Pennsylvania. Mark Marieb, MD Hartford Hospital, Hartford, CT Dr. Marieb has been in electrophysiology and arrhythmia practice in Connecticut for over 25 years. He trained in Internal Medicine, Cardiology, and Electrophysiology at Yale University/Yale New Haven Hospital. Subsequently, he joined the Cardiothoracic and Vascular Group, and in 1993 was a founding partner of the Arrhythmia Center of Connecticut, where he worked for 16 years. In 1999, he joined the full time faculty at Yale University School of Medicine, as Associate Professor of Medicine and Clinical Director of Electrophysiology Yale University School of Medicine and Yale New Haven Hospital. As of July 1, 2017, he joined Hartford Healthcare as System Director of Electrophysiology Labs for the Hartford HealthCare Heart and Vascular Institute, and also became an Associate Professor in the Department of Medicine at the University of Connecticut School of Medicine. Dr. Marieb is Board Certified in Internal Medicine, Cardiology, and Clinical Cardiac Electrophysiology. He is a Fellow of the Heart Rhythm Society (FHRS), Fellow of the American College of Cardiology (FACC), Fellow of the American Heart Association (FAHA), and a Certified Cardiac Device Specialist (CCDS). He is trained in all aspects of arrhythmia care and interventional cardiac electrophysiology. Nassir Marrouche, MD Tulane Medical Center, New Orleans, LA Dr. Marrouche received his medical degree from the Medical School at the University of Heidelberg in Germany, and has completed internships in infectious disease, pulmonary medicine and vascular surgery. After spending time at the Cleveland Clinic in Ohio, Dr. Marrouche accepted a faculty position at the University of Utah. Dr. Marrouche has dedicated his career to developing innovative research and clinical practices to advance patient care, diagnosis and treatment of heart arrhythmias. In 2009, at the University of Utah, he created the Comprehensive Arrhythmia Research and Management Center (CARMA) bringing together a cross-departmental team of physicians, scientists, researchers, MRI and imaging specialists dedicated to working collaboratively to answer the questions: What if we treated patients proactively instead of reactively? Moreover, what if we could predict and prevent a stroke in a patient before it happens? Under the guidance of Dr. Marrouche, the CARMA Center developed the Utah Classification System enabling electrophysiologists and cardiologists to deliver individualized care to arrhythmia patients. The CARMA Center also conducted the international DECAAF study. The standard of care was to ablate around the pulmonary vein. The DECAAF study showed that ablation of the veins did not predict outcome. In fact, the most important predictor of outcome, along with stage of atrial fibrosis, was the degree of ablation of the fibrotic tissue. Rather than targeting the pulmonary veins, procedures which ablated fibrotic tissue produced better outcomes. In addition to presenting his research across the globe, I am the director of the annual international Western Atrial Fibrillation Symposium.

21 Gregory Michaud, MD Vanderbilt University Medical Center, Nashville, TN Gregory F. Michaud, M.D. is a Professor of Medicine within the Division of Cardiology at Vanderbilt University School of Medicine and Chief of the Arrhythmia Section at the Vanderbilt Heart and Vascular Center. Dr. Michaud attended Haverford College in Pennsylvania prior to the University of Maryland School of Medicine. He completed Internal Medicine and Chief Medical residencies at Boston University Medical Center, and a fellowship in Cardiology and Cardiac Electrophysiology at Tufts Medical Center. Dr. Michaud began his career by investigating pacing maneuvers that allow easy diagnosis of arrhythmias in the setting of catheter ablation for supraventricular tachycardia and has broadened this approach to assist ablation operators in more complex arrhythmia cases. He is credited with at least 4 separate pacing maneuvers that are now part of core testing during specialty Board examinations for cardiac electrophysiology. Prior to arriving at Vanderbilt, he was the Director of the Center for the Advanced Management of Atrial Fibrillation at Brigham and Women’s Hospital and Associate Professor at Harvard Medical School. Dr. Michaud played a pivotal role in developing better ablation strategies for the treatment of atrial fibrillation, which is the most common arrhythmia requiring hospitalization . These include methods for assessing and improving the quality of radiofrequency ablation lesions, the result of which improves durability of pulmonary vein isolation. He recently published strategies to optimize lesion delivery by varying the amount of coolant delivered through the tip of the ablation catheter, which may limit damage to structures adjacent to the left atrium. Dr. Michaud has spoken at national and international academic conferences on his work in arrhythmia diagnosis and treatment, and authored or co-authored numerous manuscripts. He is currently co-director of the Heart Rhythm Society board review course for clinical cardiac electrophysiology and a member of the Heart Rhythm Society Scientific Sessions planning committee. He was recently elected to the Association of University Cardiologists. Damijan Miklavcic, DSc University of Ljubljana, Ljubljana, Slovenia Damijan Miklavčič was born in Ljubljana, Slovenia, in 1963. He received his PhD degree in electrical engineering from the University of Ljubljana in 1993. He is currently a tenured Professor at the Faculty of Electrical Engineering of the University of Ljubljana, where he is also the Head of the Laboratory of Biocybernetics. His current research interests include electroporation- based treatments and therapies, including cancer treatment by means of electrochemotherapy, cardiac tissue ablation by irreversible electroporation, and gene transfer for DNA vaccination. His research involves biological experimentation, numerical modeling of biological processes, and hardware development. Suneet Mittal, MD Valley Health System, Ridgewood, NJ Dr. Mittal earned his BA and MD degrees from Boston University as part of a combined 6-year BA-MD program. He did an internship and residency in internal medicine as well as a fellowship in cardiovascular diseases at the Hospital of the University of Pennsylvania in Philadelphia. He then completed a fellowship in clinical cardiac electrophysiology at the New York Presbyterian Hospital-Weill Cornell Medical Center. Dr. Mittal is board certified in cardiovascular disease and clinical cardiac electrophysiology. He is currently director of the Electrophysiology Laboratory at The Valley Hospital in Ridgewood, NJ. Dr. Mittal’s active research interests include the evaluation and management of patients with unexplained syncope, the role of implantable monitors and other cardiac devices in patients with known or suspected arrhythmias, and the clinical utility of remote monitoring of patients with a cardiac implantable electronic device. He has been an invited speaker at major academic institutions, an invited faculty member at the Annual Scientific Sessions of the American Heart Association, American College of Cardiology, and the Heart Rhythm Society, as well as an invited speaker in Europe and the Asia Pacific region. He is currently a member of the Heart Rhythm Society’s Board of Trustees. Finally, Dr. Mittal is an invited reviewer to the leading journals in cardiology and electrophysiology and serves as an editorial board member of Circulation Arrhythmia & Electrophysiology, Heart Rhythm, Journal of Interventional Cardiovascular Electrophysiology, and Journal of Noninvasive Electrocardiology.

22 Hiroshi Nakagawa, MD, PhD Cleveland Clinic, Cleveland, OH Dr. Nakagawa is an internationally recognized physician, teacher and researcher who holds a patent for a radiofrequency ablation electrode. He has research grants from the American Heart Association and the National Institutes of Health in addition to numerous industrial sponsors for developing innovations in technology. He was awarded the Medtronic Japan Fellowship Award for Young Japanese Investigators and the NASPE (North American Society of Pacing and Electrophysiology) Young Investigator Award. He is an active participant in the American Heart Association Circulation and Clinical Cardiology Sections as well as the Heart Rhythm Society. In 2007 he received the Provost’s Research Award, Senior Faculty at the University of Oklahoma Health Sciences Center. Dr. Nakagawa earned his medical degree at the Hiroshima University School of Medicine in Hiroshima, Japan. He completed a cardiology residency at the National Cardiovascular Center in Osaka, Japan; an internal medicine residency at the Hiroshima University School of Medicine in Hiroshima, Japan; an electrophysiology research fellowship at the University of Oklahoma Health Sciences Center in Oklahoma City; and a Doctorate in Cardiac Physiology at the Hiroshima University School of Medicine. His research interests include atrial fibrillation, prevention of post-infarction sudden death, and determinants of catheter ablation failure. Andrea Natale, MD Texas Cardiac Arrhythmia Institute, Austin, TX Dr. Natale is the executive medical director of Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Texas. Patients from around the world seek treatment from Dr. Natale, and his greatest reward is restoring his patients to a life free of cardiac arrhythmia. He pioneered a circumferential ultrasound vein-ablation system to correct atrial fibrillation and performed the procedure on the world’s first five patients. He also developed some of the current catheter-based cures for atrial fibrillation, and was the first electrophysiologist in the nation to perform percutaneous epicardial radiofrequency ablation, which is a treatment for people who fail conventional ablation. Moreover, he holds a patent for a device used to treat atrial fibrillation. A world-recognized leader in the field of electrophysiology, Dr. Natale is a dedicated clinician, academician and researcher. Prior to the establishment of Texas Cardiac Arrhythmia Institute at St. David’s Medical Center, Dr. Natale was a member of the Cardiovascular Medicine Department at the Cleveland Clinic from 1999 to 2007, serving most recently as section head for the Department of Cardiac Pacing and Electrophysiology and medical director for Cleveland Clinic’s Center for Atrial Fibrillation. In 2006, Dr. Natale was named to the Food and Drug Administration’s Task Force on Atrial Fibrillation. A committed academician, Dr. Natale’s faculty positions at a variety of prestigious universities include Duke and Stanford. He has been an invited lecturer at more than 200 symposiums and conferences around the world, and is the author or co-author of hundreds of published articles on pacing and electrophysiology. In addition to serving on the editorial boards of numerous medical journals, he is editor-in-chief of the Journal of Atrial Fibrillation. A forefront researcher, Dr. Natale focuses on innovative advances in the treatment of atrial fibrillation. His goal is to benefit patient care through technologies such as robotic devices and specialized ablation catheters. Saman Nazarian, MD, PhD University of Pennsylvania, Philadelphia, PA Dr. Nazarian earned a Doctorate in Medicine from Stanford University and PhD in Clinical Epidemiology from the Johns Hopkins Bloomberg School of Public Health. He completed residency at the Brigham and Women’s Hospital of Harvard Medical School, followed by fellowship training in Cardiovascular Disease and Clinical Cardiac Electrophysiology at the Johns Hopkins Hospital. As a cardiac electrophysiologist, clinical investigator, and educator, Dr. Nazarian is privileged to treat his patients with the latest evidence-based therapies. His priority is to translate his experience in electrophysiology, imaging techniques, and ablation into clinically relevant strategies for the care of his patients with cardiac arrhythmias including atrial fibrillation, supraventricular and ventricular tachycardia. He has additional expertise in treating arrhythmia in patients with neuromuscular disease. Dr. Nazarian runs an active clinical research program, funded by the US National Institutes of Health, with the goal of improving treatment strategies to reduce cardiac arrhythmia related morbidity and mortality.

23 Petr Neuzil, MD, PhD Homolka Hospital, Prague, Czech Republic Dr. Neuzil received his Doctor of Medicine from Charles University, Prague, in 1987, and his PhD in 2001. He did his residency in internal medicine at General Hospital Charles University, Prague, Czech Republic, from 1989-1991 and a fellowship in cardiology at Heart Centrum, Bad Krozingen, from 1991-1993. He worked at Beth Israel Deaconnes Medical Center (1997, 1998) and Massachusetts General Hospital (1998-2000). Dr. Neuzil is the director of cardiac arrhythmia service Na Homolce Hospital, Prague, since 2004, where he became head of cardiology in 2009. He is the director of the animal laboratory at Charles University, since 2006, and an associate professor, since 2007. He was the director of Cardiac Arrhythmias Foundation, Prague, from 2005-2007, and is a consultant at the Technology School, Prague, since 2005. Dr. Neuzil’s achievements include the development of esophageal temperature probe, research in robotic cardiac catheterization, research in electromechanical robotic catheterization system Sensei and electromagnetic navigation Niobe, and research in balloon technology in catheter ablation technology, mainly laser energy. He is the editor of the journal Practicioner, a fellow of the European Society of Cardiology and a member of European Heart Rhythm Association and Heart Rhythm Society. Douglas Packer, MD Mayo Clinic, Rochester, MN Dr. Packer is a consultant in the Division of Cardiovascular Diseases, Department of Internal Medicine, at Mayo Clinic Rochester. He is director of the Translational Electrophysiology Research Laboratory. He received his medical degree at the University of Utah and completed an internship, residency and fellowship at Duke University, where he was on staff before coming to Mayo. His honors and awards include the Distinguished Service Award from Brigham Young University. Dr. Packer is active in the Heart Rhythm Society, where was president from he 2011-2012. He was also the international principal investigator of the CABANA Pivotal Study. Eric Prystowsky, MD St. Vincent Hospital, Indianapolis, IN Dr. Prystowsky is a practicing Cardiologist with St. Vincent Medical Group and Director of the Cardiac Arrhythmia Service, St. Vincent Hospital, Indianapolis. He is also a Consulting Professor of Medicine at Duke University Medical Center. Dr. Prystowsky is a graduate of Pennsylvania State University and the Mt. Sinai School of Medicine. He completed his internal medicine training at Mt. Sinai Hospital, New York City, and his training in cardiology and clinical electrophysiology at Duke University Medical Center, Durham, North Carolina. From 1979 to 1986, Dr. Prystowsky was a full-time faculty member at the Indiana University School of Medicine, where he was Director of the Electrophysiology Laboratory. In 1986, he returned to Duke University as Professor of Medicine and Director of the Cardiac Arrhythmia Center. He joined St. Vincent in 1988. In addition to co-authoring two textbooks, Cardiac Arrhythmias: An Integrated Approach for the Clinician; and Clinical Electrophysiology Review, Dr. Prystowsky has also authored over 700 publications concerning cardiac arrhythmias. He is the Editor- in-Chief of The Journal of Cardiovascular Electrophysiology and is also on the editorial board of 15 journals. Vivek Reddy, MD Mount Sinai Medical Center, New York, NY Dr. Reddy is the Leona Helmsley Professor of Cardiovascular Electrophysiology at Mount Sinai Medical Center, and the director of Cardiac Electrophysiology at Mount Sinai Heart. Dr. Reddy attended medical school at the University of Michigan. He completed internal medicine residency training at Yale University, cardiology fellowship training at the University of Chicago Hospitals, and cardiac electrophysiology training at Massachusetts General Hospital. After completing the training, he joined the medical staff of Massachusetts General Hospital, where he served as director of the Experimental Electrophysiology Laboratory.

24 Jeremy Ruskin, MD Massachusetts General Hospital, Boston, MA Dr. Ruskin is Professor of Medicine at Harvard Medical School and Founder and Director Emeritus of the Cardiac Arrhythmia Service at Massachusetts General Hospital (MGH). In 1978, Dr. Ruskin founded the Cardiac Arrhythmia Service and Clinical Cardiac Electrophysiology Fellowship Training Program at MGH. This was the first subspecialty service dedicated to the care of patients with cardiac arrhythmias and the first subspecialty training program in cardiac electrophysiology in New England and one of the first in the United States. Dr. Ruskin has been responsible for the training and mentorship of more than 115 clinical and research fellows in the subspecialty of cardiac arrhythmias, many of whom are in leadership positions at academic centers throughout the world. His research focuses on atrial fibrillation, sudden cardiac death, and new approaches to the prevention of cardiac fibrosis. Dr. Ruskin is the recipient of the 1997 Michel Mirowski Award for Excellence in Clinical Cardiology and Electrophysiology, the 2002 Heart Rhythm Society Pioneer in Pacing and Electrophysiology Award and the 2015 KCHRS Pioneer in Electrophysiology Award. He was named the inaugural incumbent of the Omran Alomran Endowed Chair in Cardiology at Massachusetts General Hospital in 2016. Walid Saliba, MD Cleveland Clinic, Cleveland, OH Dr. Walid Saliba is a staff cardiologist in the Section of Cardiac Electrophysiology and Pacing in the Department of Cardiovascular Medicine at Cleveland Clinic. Dr. Saliba is also the Medical Director of the EP lab and Director of the Atrial Fibrillation Center. He is trained in all aspects of clinical cardiac electrophysiology and pacing, including catheter ablation, epicardial access, LAA occlusion, implantation of cardiac pacemakers and defibrillators and extraction of implanted pacemaker and ICD leads using laser technology. A native of Lebanon, Dr. Saliba did his undergraduate work at the American University of Beirut, continued at the American University and earned his medical degree. He is fluent in English, French and Arabic. He moved to the United States where he completed an internship and residency program in internal medicine at Duke University, a fellowship in Cardiology from Baylor College. The Cleveland Clinic awarded him a fellowship in cardiac electrophysiology and he was appointed to Cleveland Clinic as a staff cardiac electrophysiologist in 1999. Dr. Saliba’s research has focused on topics related to new treatments of atrial fibrillation, stroke prevention strategies and pericardial ablation. He has been a guest lecturer and authored or co-authored numerous articles in leading scientific journals. Jacqueline Saw, MD Vancouver General Hospital, Vancouver, BC, Canada Dr. Saw is an interventional cardiologist at Vancouver General Hospital (VGH) with joint appointment at St. Paul’s Hospital. She is a Clinical Professor of Medicine at the University of British Columbia, and director of the Interventional Cardiology Fellowship Program at VGH. Dr. Saw is a pioneer and leader in research and management of spontaneous coronary artery dissection (SCAD), and is the principal investigator of the Canadian Institutes of Health Research-funded multicenter prospective Canadian SCAD Study, and the Heart and Stroke Foundation-funded Canadian SCAD Genetic Study. Other research interests include LAA closure, non-atherosclerotic coronary artery disease, antiplatelet therapy, percutaneous coronary intervention, carotid artery stenting, peripheral arterial disease and intervention. She is also the principal investigator of PRYME, NACAD, SAFER-SCAD, Canadian WATCHMAN Registry, TAP-CABG, and ELAPSE studies. Ulrich Schotten, MD, PhD University Maastricht, Maastricht, Netherlands Professor Schotten studied medicine at the universities of Aachen, Glasgow and Valetta. After 4 years of training in cardiology at the University Hospital of Aachen, he defended his thesis “Mechanisms of Atrial Paralysis in Atrial Fibrillation” at Maastricht University. In 2011, he was appointed professor of cardiac electrophysiology at the Department of Physiology in Maastricht. His research programme ranges from the molecular and cellular investigations to studies on the organ and systemic level. He currently works on cellular and integrated actions of antiarrhythmic drugs, the development of substrates for the perpetuation of atrial fibrillation, invasive and non-invasive quantification of the substrate of atrial fibrillation, interaction between atrial fibrillation and activation of the coagulation system, and three-dimensional computer models. Prof. Schotten is PI or coordinator of numerous national and international research networks and has been member of the European task force for the development of the ESC guidelines for management of atrial fibrillation in 2010 and 2016.

25 Andrew J. Sherman, MD St. Joseph’s Hospital, Tampa, FL Dr. Andrew Sherman is board certified in thoracic and cardiac surgery. He serves as chief of the Department of Cardiothoracic Surgery at St. Joseph’s Hospital (SJH). He is also one of the founding members of the Transcatheter aortic valve replacement (TAVR) team at SJH and serves as the lead surgeon of a new minimally invasive treatment for patients with atrial fibrillation. Dr. Sherman trains electrophysiologists and surgeons throughout the country in this particular operation. Dr. Sherman earned his Doctor of Medicine from Rush University Medical College in Durham, North Carolina. He then completed a general surgery residency at McGaw Medical Center of Northwestern University in Chicago, Illinois and a cardiothoracic surgery residency at Emory Univeristy in Atlanta, Georgia. Dr. Sherman then completed fellowships in surgical research from Feinberg Cardiovascular Research Institute in Chicago, Illinois and cardiothoracic surgery from Emory, to complete his medical education. Dr. Sherman specializes in beating heart surgery, valvular heart disease, TAVR, complex aortic valve and root disorders, and minimally invasive lung surgery with extensive experience in video-assisted thoracic surgery (VATS) procedures including total thoracoscopic lobectomies. He belongs to the Society of Thoracic Surgeons and is an executive cabinet member of the American Heart Association’s Tampa Bay Heart Ball. Daniel Singer, MD Massachusetts General Hospital, Boston, MA Dr. Singer is Professor of Medicine at Harvard Medical School and Professor in the Department of Epidemiology at Harvard School of Public Health. At Massachusetts General Hospital, he is Director of the General Medicine Research Fellowship. Dr. Singer is widely recognized for his research contributions in clinical epidemiology and preventive medicine, in particular, the prevention of stroke in atrial fibrillation. He received the 2003 John Eisenberg Award from the National Society for General Internal Medicine for Career Achievements in Research, and the 2008 C. Miller Fisher Award from the New England chapter of the American Stroke Association/American Heart Association for his contributions to stroke research. Claudio Tondo, MD, PhD University of Milan, Milan, Italy Prof. Tondo is a professor of cardiology and director of the Cardiac Arrhythmia Research Center of Centro Cardiologico Monzino-University of Milan. A world-recognized leader in the field of electrophysiology, Prof. Tondo is a dedicated clinician and researcher. He has been director of the Cardiac Arrhythmia and Heart Failure Research Institute, San Camillo-Forlanini Hospital, and co-director of the Electrophysiology Experimental Laboratory, Catholic University of Sacred Heart, in Rome, Italy. Prof. Tondo has been an invited lecturer at more than 100 symposiums and conferences around the world and is the author or co-author of hundreds of published articles on pacing and electrophysiology. Since 2007, he is a visiting professor at Harvard Medical School in Boston. Prof. Tondo and his team focus on innovative advances in the treatment of atrial fibrillation through the most advanced technologies, such as robotic devices and specialized ablation catheters. He is a regular member of North American Society of Pacing and Electrophysiology and Italian Society of Arrhythmology. Natalia Trayanova, PhD Johns Hopkins University, Baltimore, MD Dr. Trayanova is the Murray B. Sachs Professor in the Department of Biomedical Engineering at Johns Hopkins University The focus of her research is on computational cardiac electrophysiology, with emphasis on cardiac arrhythmia mechanisms and on novel anti-arrhythmia therapeutic methodologies. Her translational research has laid the foundation for novel technological developments, enabling the construction of clinical-imaging-based models of human hearts that realistically represent the functioning of the diseased organ. Using a personalized simulation approach, Dr. Trayanova has developed new methods for predicting risk of cardiac arrest and improving the accuracy of atrial and ventricular catheter ablation therapies. Through her first-of-their-kind personalized virtual hearts, she is pioneering advances in personalized medicine for patients with cardiovascular disease, which promise to influence clinical decision-making and the delivery of patient care.

26 Mintu Turakhia, MD VA Palo Alto & Stanford University, Stanford, CA Mintu Turakhia M.D. M.A.S. is a cardiac electrophysiologist, outcomes researcher, and clinical trialist. He is the Director of the Stanford Center for Digital Health. Dr. Turakhia has an active multidisciplinary program in heart rhythm research, where uses biostatistical, health economic, artificial intelligence, and data science approaches to examine quality, outcomes, and risk of heart rhythm disorders such as atrial fibrillation in very large datasets. He is a principal investigator of several multi-center trials, such as the Apple Heart Study, to test digital health tools and wearables and collaborates closely on research with med device and tech companies. He performs invasive procedures such as catheter ablation and device implantation to treat heart rhythm disorders. Dr. Turakhia has published over 200 manuscripts and works and is an elected member of the American Society of Clinical Investigation and a Fellow of the American College of Cardiology, American Heart Association, and Heart Rhythm Society. Dr. Turakhia has served as an advisor and investor to over 25 medical device, drug, and health technology companies across the life cycle from early stage to IPO Albert Waldo, MD University Hospitals of Cleveland, Cleveland, OH Dr. Waldo is the Walter H. Pritchard Professor of Cardiology, Professor of Medicine, and a Professor of Medicine and Biomedical Engineering at Case Western University School of Medicine in Cleveland, Ohio. He has published more than 450 papers in the field of cardiac electrophysiology, in which he has worked, and helped to advance since its inception several decades ago. He has received numerous awards, including the Distinguished Scientist Awards from NASPE (now called HRS), and the American College of Cardiology. His extensive public service has included serving on NIH NHLBI study sections, and FDA advisory committees; President and Trustee of NASPE, and editorial board of numerous Journals in the field. Paul Wang, MD Stanford University Medical Center, Stanford, CA Dr. Wang is the Director of the Stanford Cardiac Arrhythmia Service and Professor of Medicine and of Bioengineering (by courtesy). He has co-authored textbooks on implantable defibrillators, sudden cardiac death, cardiac resynchronization/ biventricular pacing therapy, and innovations in arrhythmia therapy. Dr. Wang participates on numerous national boards and panels in cardiac electrophysiology. Dr. Wang has been selected as the Editor-in-Chief of one of the field’s most pre-eminent journals, Circulation: Arrhythmia and Electrophysiology. He is a member of the American Heart Association Council on Clinical Cardiology, a member of the American Heart Association Science and Clinical Education Lifelong Learning (SCILL) Committee, and past Chair of the American Heart Association Council on Clinical Cardiology ECG and Arrhythmias Committee and the past member of the American College of Cardiology Electrophysiology Committee. He helped found the American Heart Association Arrhythmia Research Summit at the AHA Annual Scientific Sessions. He was previously a member of the Cardiac Electrophysiology Board Certification Exam Writing Committee of the American Board of Internal Medicine. He was past Chair of the CME Compliance Subcommittee and Vice-Chair of the Education Committee of the Heart Rhythm Society. He was an Associate Editor of the Heart Rhythm Journal. He is a former member of the Board of Trustees of the Heart Rhythm Society. Dr. Wang is Co-Director of the Bioengineering Scholarly Concentration of the Stanford School of Medicine. Dr. Wang directs the course Bioengineering 390, Introduction to Bioengineering Research. Dr. Wang with Dr. Paul Yock organizes an annual meeting, “Stanford Biodesign New Arrhythmia Technologies Retreat”, focusing on new technological advances in arrhythmia management and diagnosis. Dr. Wang is a member of the Stanford Biodesign Center program committee and the Center’s Faculty Liaison. Dr. Wang’s research studies centers on the development of innovative approaches to the treatment of arrhythmias, including catheter ablation, implantable devices, and diagnostic techniques. Dr. Wang has invented a number of new arrhythmia technologies and has 17 issued patents. Dr. Wang is co-inventor of a cryoablation method and device that has been the basis of a cryoablation catheter which has been FDA approved (Cryocath, Inc. acquired by Medtronic, Inc.). Catheter cryoablation has been used in over 250,000 patients with atrial fibrillation and supraventricular tachycardias. Dr. Wang published the first report of balloon cryoablation in 2006. More recently, Dr. Wang has invented and patented a catheter device that is designed to walk on the inner surface of the heart. Dr. Wang has developed algorithms to improve rhythm detection including a technique for T wave subtraction to identify the P wave morphology of atrial arrhythmias. Recently Dr. Wang coauthored a best practices guide for cryoablation of atrial fibrillation based on 3000 procedures. Dr. Wang actively participates in FIRM related research and uses FIRM mapping regularly.

27 David Wilber, MD Loyola University Medical Center, Chicago, IL Dr. Wilber is the George M. Eisenberg Professor of Medicine and director of both the Division of Cardiology, Department of Medicine, Loyola University Chicago Stritch School of Medicine and the Cardiovascular Institute. Dr. Wilber first joined Loyola University Chicago Stritch School of Medicine in 1984 as an assistant professor. He left 10 years later to join University of Chicago Pritzker School of Medicine as a professor. He returned to Loyola in 2001 to head the Cardiovascular Institute, where he directs educational efforts and cardiology clinical services. Dr. Wilber received his medical degree from Northwestern University Medical School and completed his residency in internal medicine at Northwestern Memorial Hospital, both in Chicago, Illinois. He completed a fellowship in cardiovascular disease at the University of Michigan Hospitals and another in clinical cardiac electrophysiology at Massachusetts General Hospital. His distinguished career as an internationally renowned expert in cardiac electrophysiology includes additional faculty positions with Harvard Medical School, the University of Michigan Medical School and Northwestern University Medical School. Roger Winkle, MD Silicon Valley Cardiology, Palo Alto, CA Dr. Roger Winkle obtained a BS in Electrical Engineering from Cornell University, and attended the University of Cincinnati Medical School. He did internship and residency at Washington University and Barnes Hospital and went to Stanford University for cardiology training. His early research interests included ambulatory ECG monitoring, arrhythmias in obstructive sleep apnea and the clinical pharmacology of antiarrhythmic drugs. At Stanford he became a tenured faculty member and cofounded one of the first academic arrhythmia services. In 1984 he founded Silicon Valley Cardiology, one of the first private EP groups in the US. He helped develop the modern ICD, was involved in the open-heart surgical mapping of almost 1000 cases of VT, WPW, and AVNRT and has performed thousands of RF ablations. He described proarrhythmia from Type 1C antiarrhythmic drugs and introduced catheter based human defibrillation with a biphasic waveform. He began his ablation research with high energy DC ablation and helped develop one of the first steerable RF ablation catheter systems. His current research interests include evaluating procedural techniques for and the outcomes of atrial fibrillation RF ablation and the use of ultra high-density mapping for atrial arrhythmias. Felix Yang, MD Maimonides Medical Center, , NY Dr. Felix Yang, MD, FACC, FHRS is Associate Director of Cardiac Electrophysiology and Director of the Lead Extraction Service at Maimonides Medical Center in Brooklyn, New York. Dr. Yang completed his medical school, internship and residency training at Cornell (NY Presbyterian Hospital) where he was an Assistant Chief Resident. He subsequently completed his fellowship in Cardiovascular Medicine at Beth Israel Medical Center, where he served as Chief Fellow, and a second fellowship in Cardiac Electrophysiology at Montefiore Medical Center. He focused on atrial fibrillation outcomes research at VA Palo Alto following his EP fellowship and continues to be active in research as an investigator in multiple cutting edge EP technologies and procedures. His practice focuses on device implantation as well as ablation of atrial fibrillation and ventricular tachycardia. Dr. Yang is a member of several professional organizations and is a Fellow of the American College of Cardiology and the Heart Rhythm Society.

28